One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

Key Points Interested in Apple Inc.? Here are five stocks we like better. While the AI trade corrects, blue-chip stocks ...

Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read ...

Johnson & Johnson (NYSE: JNJ) stock jumped 3.4% through 12:20 p.m. ET Friday after Guggenheim analyst Vamil Divan raised his price target on the already buy-rated stock to $270 per share. Johnson & ...

Johnson & Johnson (NYSE: JNJ) is one of the largest healthcare companies in the world. But it hasn't always been a terribly exciting business to invest in. While it has been growing, it's typically ...

It can provide some stability during volatile times.

Bristol Myers Squibb operates as a pure-play biopharmaceutical company focusing on serious diseases. The company develops and sells medicines in the healthcare stocks sector across oncology, ...

Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company’s Moderate operating performance ...

Recent chatter on X about Johnson & Johnson (JNJ) has been buzzing with reactions to the company's latest earnings report and raised 2024 guidance. Posts highlight a notable 6% stock price increase ...